The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Neutralization of IFNγ defeats haemophagocytosis in LCMV‐infected perforin‐ and Rab27a‐deficient mice
Open accessAbstract
Hereditary haemophagocytic lymphohistiocytosis (HLH) is a fatal inflammatory disease and treatments currently may lead to serious side effects. There is a pressing need for effective, less toxic treatments for this disease. Previous reports have suggested that interferon gamma (IFNgamma) has a role in the pathogenesis of HLH. Here, we report that blocking IFNgamma had a therapeutic effect in two different murine models of human hereditary HLH (perforin-deficient and Rab27a-deficient mice, both infected with lymphocytic choriomeningitis virus). Therapeutic administration of an anti-IFNgamma antibody induced recovery from haemophagocytosis in both genetic models, as evidenced by increased survival in perforin-deficient mice and correction of blood cytopenia, moderation of body temperature changes, decreased cytokinaemia, restoration of splenic architecture and reduced haemophagocytosis in the liver of both murine models. Involvement of the central nervous system in Rab27a-deficient mice was prevented by anti-IFNgamma therapy. Hepatic T-cell infiltrates and virus persisted, with no detectable harm during the time course of these studies. These data strongly suggest that neutralization of IFNgamma could be used in humans to safely alleviate the clinical manifestations of haemophagocytosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Hypercytokinemia in familial hemophagocytic lymphohistiocytosis
Henter, J., Elinder, G., Soder, O., Hansson, M., Andersson, B., & Andersson, U. (1991) · Blood · doi:10.1182/blood.v78.11.2918.2918 · Cited by 505
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Mazodier, K. (2005) · Blood · doi:10.1182/blood-2005-05-1980 · Cited by 290
Cited by
Hematological Problems in Pediatric Intensive Care
Revel-Vilk, S., Cox, P., Robitaille, N., & Blanchette, V. (2014) · Pediatric and Adolescent Medicine · doi:10.1159/000350346 · Cited by 3,508
Fajgenbaum, D. C., & June, C. H. (2020) · New England Journal of Medicine · doi:10.1056/nejmra2026131 · Cited by 3,196
How I treat hemophagocytic lymphohistiocytosis
Jordan, M. B., Allen, C. E., Weitzman, S., Filipovich, A. H., & McClain, K. L. (2011) · Blood · doi:10.1182/blood-2011-03-278127 · Cited by 1,148
Bergsten, E., Horne, A., Aricó, M., Astigarraga, I., Egeler, R. M., Filipovich, A. H., Ishii, E., Janka, G., Ladisch, S., Lehmberg, K., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788349 · Cited by 677
Familial and Acquired Hemophagocytic Lymphohistiocytosis
Janka, G. E. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-041610-134208 · Cited by 549
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
Locatelli, F., Jordan, M. B., Allen, C., Cesaro, S., Rizzari, C., Rao, A., Degar, B., Garrington, T. P., Sevilla, J., Putti, M.-C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911326 · Cited by 534
Hemophagocytic syndromes — An update
Janka, G. E., & Lehmberg, K. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.03.002 · Cited by 461
Macrophage activation syndrome in the era of biologic therapy
Grom, A. A., Horne, A., & De Benedetti, F. (2016) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.179 · Cited by 448
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T.-D. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 438
Jordan, M. B., Allen, C. E., Greenberg, J., Henry, M., Hermiston, M. L., Kumar, A., Hines, M., Eckstein, O., Ladisch, S., Nichols, K. E., et al. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.27929 · Cited by 424
Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
Schulert, G. S., & Grom, A. A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-012806 · Cited by 402
Weiss, E. S., Girard-Guyonvarc’h, C., Holzinger, D., de Jesus, A. A., Tariq, Z., Picarsic, J., Schiffrin, E. J., Foell, D., Grom, A. A., Ammann, S., et al. (2018) · Blood · doi:10.1182/blood-2017-12-820852 · Cited by 395
Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice
Behrens, E. M., Canna, S. W., Slade, K., Rao, S., Kreiger, P. A., Paessler, M., Kambayashi, T., & Koretzky, G. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43157 · Cited by 392
“IFN-γ is the central cytokine mediating primary HLH syndromes, and neutralization of this antibody ameliorates disease (8, 22).”
BackgroundRavelli, A., Grom, A. A., Behrens, E. M., & Cron, R. Q. (2012) · Genes & Immunity · doi:10.1038/gene.2012.3 · Cited by 386
Hemophagocytic lymphohistiocytosis: pathogenesis and treatment
Janka, G. E., & Lehmberg, K. (2013) · Hematology · doi:10.1182/asheducation-2013.1.605 · Cited by 325
Review: Cytokine Storm Syndrome: Looking Toward the Precision Medicine Era
Behrens, E. M., & Koretzky, G. A. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40071 · Cited by 304
Bracaglia, C., de Graaf, K., Pires Marafon, D., Guilhot, F., Ferlin, W., Prencipe, G., Caiello, I., Davì, S., Schulert, G., Ravelli, A., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-209020 · Cited by 290
Self-citationde Jesus, A. A., Canna, S. W., Liu, Y., & Goldbach-Mansky, R. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112227 · Cited by 282
Jenkins, M. R., Rudd-Schmidt, J. A., Lopez, J. A., Ramsbottom, K. M., Mannering, S. I., Andrews, D. M., Voskoboinik, I., & Trapani, J. A. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140964 · Cited by 258
Ahmed, A., Merrill, S. A., Alsawah, F., Bockenstedt, P., Campagnaro, E., Devata, S., Gitlin, S. D., Kaminski, M., Cusick, A., Phillips, T., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30156-5 · Cited by 256
Das, R., Guan, P., Sprague, L., Verbist, K., Tedrick, P., An, Q. A., Cheng, C., Kurachi, M., Levine, R., Wherry, E. J., et al. (2016) · Blood · doi:10.1182/blood-2015-12-684399 · Cited by 254
Hemophagocytosis causes a consumptive anemia of inflammation
Zoller, E. E., Lykens, J. E., Terrell, C. E., Aliberti, J., Filipovich, A. H., Henson, P. M., & Jordan, M. B. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20102538 · Cited by 228
Brisse, E., Wouters, C. H., & Matthys, P. (2016) · British Journal of Haematology · doi:10.1111/bjh.14147 · Cited by 197
Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells
Xu, X.-J., & Tang, Y.-M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.10.004 · Cited by 156
Avau, A., Mitera, T., Put, S., Put, K., Brisse, E., Filtjens, J., Uyttenhove, C., Van Snick, J., Liston, A., Leclercq, G., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38359 · Cited by 90
Pardeo, M., Bracaglia, C., & De Benedetti, F. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.02.002 · Cited by 60
Bacterial stimulation of toll-like receptor 4 drives macrophages to hemophagocytose
McDonald, E. M., Pilonieta, M. C., Nick, H. J., & Detweiler, C. S. (2016) · Infection and Immunity · doi:10.1128/iai.01149-15 · Cited by 18
Metadata
- Authors
- Schmid, J. P., Ho, C., Chrétien, F., Lefebvre, J. M., Pivert, G., Kosco‐Vilbois, M., Ferlin, W., Geissmann, F., Fischer, A., & de Saint Basile, G.
- Venue
- EMBO Molecular Medicine
- Published
- 2009-05
- Volume
- 1
- Issue
- 2
- Pages
- 112-124
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W2133819747
- Cited by
- 196
- References
- 3
- FWCI
- 4.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.